Deutsche Bank AG Makes New Investment in Neurogene Inc. $NGNE

Deutsche Bank AG purchased a new stake in shares of Neurogene Inc. (NASDAQ:NGNE) in the second quarter, Holdings Channel.com reports. The institutional investor purchased 106,660 shares of the company’s stock, valued at approximately $3,354,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in NGNE. BNP Paribas Financial Markets lifted its position in shares of Neurogene by 89.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after purchasing an additional 978 shares during the last quarter. State of Wyoming acquired a new stake in Neurogene in the 2nd quarter valued at approximately $31,000. ADAR1 Capital Management LLC increased its position in Neurogene by 3.4% in the 3rd quarter. ADAR1 Capital Management LLC now owns 30,633 shares of the company’s stock worth $531,000 after buying an additional 1,008 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Neurogene by 17.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after buying an additional 1,059 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Neurogene by 12.8% during the first quarter. Bank of New York Mellon Corp now owns 26,043 shares of the company’s stock worth $525,000 after buying an additional 2,950 shares during the last quarter. 52.37% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Neurogene

In other Neurogene news, CFO Christine Mikail Cvijic sold 4,200 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $36.13, for a total transaction of $151,746.00. Following the completion of the transaction, the chief financial officer owned 84,040 shares in the company, valued at $3,036,365.20. This trade represents a 4.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 9,600 shares of company stock valued at $339,932 over the last three months. Corporate insiders own 11.68% of the company’s stock.

Neurogene Price Performance

Shares of Neurogene stock opened at $38.41 on Thursday. Neurogene Inc. has a 52-week low of $15.93 and a 52-week high of $43.66. The firm has a market capitalization of $768.58 million, a PE ratio of -7.64 and a beta of 1.70. The company’s fifty day moving average price is $35.58 and its two-hundred day moving average price is $28.09.

Neurogene (NASDAQ:NGNE) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($1.53) EPS for the quarter, missing analysts’ consensus estimates of ($1.42) by ($0.11). Analysts predict that Neurogene Inc. will post -5.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on NGNE shares. Canaccord Genuity Group reduced their price objective on Neurogene from $180.00 to $166.00 and set a “buy” rating for the company in a research report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a research note on Friday, July 17th. UBS Group set a $70.00 price target on shares of Neurogene in a research report on Wednesday, June 3rd. Guggenheim boosted their price objective on shares of Neurogene from $69.00 to $81.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, Rodman & Renshaw began coverage on shares of Neurogene in a research report on Wednesday, June 3rd. They set a “buy” rating and a $70.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $83.67.

Neurogene Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.